<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140761</url>
  </required_header>
  <id_info>
    <org_study_id>COPTRIN</org_study_id>
    <nct_id>NCT03140761</nct_id>
  </id_info>
  <brief_title>The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene</brief_title>
  <official_title>The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the correlation between four well-known polymorphisms of the glucocorticoid
      receptor gene (two with reduced sensitivity versus two with increased sensitivity) and the
      prevalence of secondary adrenal insufficiency in glucocorticoid-treated patients with
      exacerbation of COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD patients who have received systemic glucocorticoid exceeding the equivalent of 180 mg
      prednisolone which are homo / heterozygous for the BclI and / or N363S polymorphisms
      (associated with increased glucocorticoid sensitivity) will have a lower cortisol response in
      a synacthen® test (greater suppression of adrenal corticosteroid) than the corresponding
      patients there are wild-type or homo- or heterozygous for the polymorphic ER22 / 23EK and /
      or 9β (associated with decreased sensitivity). Information from the results of the
      investigation will be able to help clinicians to identify patients with acute exacerbation of
      COPD (AECOPD) at risk of of secondary adrenal insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Actual">May 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Secondary Adrenal insufficiency</measure>
    <time_frame>average 1 month</time_frame>
    <description>test for adrenal function by stimulation test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic syndrome</measure>
    <time_frame>average 1 month</time_frame>
    <description>blood lipids, blood pressure, plasma glucose, abdominal obesity, body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral loss</measure>
    <time_frame>average 1 month</time_frame>
    <description>bonemarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Diabetes Mellitus</measure>
    <time_frame>average 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>average 1 month</time_frame>
    <description>test by questionnaires</description>
  </secondary_outcome>
  <enrollment type="Actual">78</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples and DNA from gene analyses
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        78 hospitalised patients with exacerbation of COPD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt; 18 years

          -  Caucasian classified with COPD

          -  Patients with AECOPD being treated with at least 5 days of glucocorticoid (minimum of
             180 mg)

        Exclusion Criteria:

          -  Treated with estrogen-containing medications, including anticonceptiva 6 weeks prior
             to Synacthen®

          -  Pregnancy or lactation

          -  on regular systemic glucocorticoid therapy before admission to the hospital

          -  People who are detained under the act on the use of coercion in psychiatry

          -  Severe language problems or inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Internal medicine, Herlev &amp; Gentofte Universtity Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</investigator_affiliation>
    <investigator_full_name>Pradeesh Sivapalan</investigator_full_name>
    <investigator_title>MD, Phd fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

